Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 17Lymphoid 8Myeloid 3Tumor-Agnostic 2Plasma cell 2Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 172Glioblastoma 72Gliosarcoma 70Brain Neoplasms 41Osteosarcoma 40Neoplasms 40Astrocytoma 38Recurrence 35Melanoma 33Oligodendroglioma 32Gastrointestinal Stromal Tumors 31Breast Neoplasms 31Glioma 30Lymphoma 29Dendritic Cell Sarcoma, Interdigitating 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Neoplasm Metastasis 28Central Nervous System Neoplasms 27Burkitt Lymphoma 26Bone Neoplasms 26Ovarian Neoplasms 25Colorectal Neoplasms 24Neuroblastoma 22Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Stomach Neoplasms 21Sarcoma, Ewing 21Lung Neoplasms 19Leukemia, Myeloid, Acute 19Leukemia 19

Interventions

Cyclophosphamide 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm, Residual × Sarcoma × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡